The role of complement in the generation of autoantibodies that frequently associate with kidney disease is not well understood. Furthermore, the role of autoantibodies targeting complement proteins in driving the pathology of many kidney diseases remains an enigma. Nevertheless, their presence remains an important factor in deciding whether treatment with drugs such as Eculizumab and Rituximab is appropriate. Therefore, novel methods for the detection and comprehensive evaluation of the functional relevance of these autoantibodies and other autoantibodies that associate with renal disease will be key for guiding clinical decisions. Pathways leading to autoantibody-induced pathology greatly differ among different diseases, and autoantibodies directed against the same antigen, depending on the targeted epitope, can have diverse effects. Understanding the cross talk between complement and autoantibody-based pathologies will provide unique opportunities to understand the pathology in kidney diseases and beyond.
To foster knowledge in autoantibody-induced pathology with complement involvement in the kidney and to encourage the development of urgently needed novel therapeutic strategies, we aim to stimulate a vivid discussion of current treatment and interest in autoimmune kidney diseases in this Research Topic. We welcome the submission of Review, Mini-Review and Original Research articles, including comprehensive Method articles on novel diagnostic techniques, considering all aspects of autoantibodies in kidney diseases . This includes their generation, morphology (i.e. glycosylation status) in health and disease, as well as the diverse mechanisms by which they lead to or are a consequence of autoimmune kidney disease. In particular, we welcome articles that discuss the following areas of interest:
1. Factor H autoantibodies (AAb).
2. Factor B AAb.
3. Anti-C1q AAb.
4. Novel and/or emerging AAbs in kidney diseases.
5. Targeting AAb as a viable treatment for kidney diseases.
6. The use of eculizumab in the presence of autoantibodies.
7. Current challenges in the laboratory diagnosis of AAbs.
8. Nephritic Factors.
9. AAb in Hypocomplementemic Urticarial Vasculitis Syndrome.
10. AAb in ANCA-associated vasculitis.
11. AAb in IgA nephropathy.
12. Anti PLA2R+ membranous nephropathy.
13. Anti-complement AAb in Lupus Nephritis.
14. AAb in C3G.
15. AAb in aHUS.
The role of complement in the generation of autoantibodies that frequently associate with kidney disease is not well understood. Furthermore, the role of autoantibodies targeting complement proteins in driving the pathology of many kidney diseases remains an enigma. Nevertheless, their presence remains an important factor in deciding whether treatment with drugs such as Eculizumab and Rituximab is appropriate. Therefore, novel methods for the detection and comprehensive evaluation of the functional relevance of these autoantibodies and other autoantibodies that associate with renal disease will be key for guiding clinical decisions. Pathways leading to autoantibody-induced pathology greatly differ among different diseases, and autoantibodies directed against the same antigen, depending on the targeted epitope, can have diverse effects. Understanding the cross talk between complement and autoantibody-based pathologies will provide unique opportunities to understand the pathology in kidney diseases and beyond.
To foster knowledge in autoantibody-induced pathology with complement involvement in the kidney and to encourage the development of urgently needed novel therapeutic strategies, we aim to stimulate a vivid discussion of current treatment and interest in autoimmune kidney diseases in this Research Topic. We welcome the submission of Review, Mini-Review and Original Research articles, including comprehensive Method articles on novel diagnostic techniques, considering all aspects of autoantibodies in kidney diseases . This includes their generation, morphology (i.e. glycosylation status) in health and disease, as well as the diverse mechanisms by which they lead to or are a consequence of autoimmune kidney disease. In particular, we welcome articles that discuss the following areas of interest:
1. Factor H autoantibodies (AAb).
2. Factor B AAb.
3. Anti-C1q AAb.
4. Novel and/or emerging AAbs in kidney diseases.
5. Targeting AAb as a viable treatment for kidney diseases.
6. The use of eculizumab in the presence of autoantibodies.
7. Current challenges in the laboratory diagnosis of AAbs.
8. Nephritic Factors.
9. AAb in Hypocomplementemic Urticarial Vasculitis Syndrome.
10. AAb in ANCA-associated vasculitis.
11. AAb in IgA nephropathy.
12. Anti PLA2R+ membranous nephropathy.
13. Anti-complement AAb in Lupus Nephritis.
14. AAb in C3G.
15. AAb in aHUS.
